Disclosures for "Smartphone Software Application-mediated At-home Telespirometry (AHT) Artificial Intelligence(AI)-algorithm Identifies Similar Proportion of Valid Erect (eFVC) and Supine (sFVC) Forced Vital Capacity Measurements and Comparable per Subject Test-ReTest Variability Above and Below Forced Vital Capacity 60% Predicted in an Amyotrophic Lateral Sclerosis (ALS) Clinic Population"
-
Mr. Slavinski has nothing to disclose.
-
The institution of Dr. Young has received research support from Mitsubishi Tanabe Pharma America.
-
Dr. Wang has nothing to disclose.
-
Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ITF Pharma. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Cytokinetics. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Muscular Dystrophy Association. The institution of Dr. Brooks has received research support from Orion. Dr. Brooks has received research support from Alexion. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. The institution of Dr. Brooks has received research support from Biohaven. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with American Academy of Neurology that is relevant to AAN interests or activities.